- Home
- SIEB vs CHRS Comparison
SIEB vs CHRS Comparison
Compare SIEB & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SIEB | CHRS |
|---|---|---|
| Founded | 1886 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.1M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SIEB | CHRS |
|---|---|---|
| Price | $3.02 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.02 |
| AVG Volume (30 Days) | 15.3K | ★ 1.2M |
| Earning Date | 11-12-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.18 | ★ 1.34 |
| Revenue | $90,289,000.00 | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.31 |
| P/E Ratio | $17.05 | ★ $1.23 |
| Revenue Growth | 8.32 | ★ 152.07 |
| 52 Week Low | $2.08 | $0.71 |
| 52 Week High | $5.77 | $1.89 |
Technical Indicators
Market Signals| Indicator | SIEB | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 55.52 |
| Support Level | $2.92 | $1.51 |
| Resistance Level | $3.24 | $1.72 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 8.70 | 54.33 |
Price Performance
Historical ComparisonAbout SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.